Tasly Pharmaceutical Group Co Ltd

Common Name
Tasly Pharmaceutical Group
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
10,958
Ticker
600535
Exchange
SHANGHAI STOCK EXCHANGE
Description
Tasly Pharmaceutical Group Co., Ltd. is a prominent entity in the pharmaceutical industry, primarily involved in the research, development, production, and marketing of modern Traditional Chinese Medi...

Financial Statements of Tasly Pharmaceutical Group

Below are the financial statements of Tasly Pharmaceutical Group, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in millions of CNY20242023
Current assets
Monetary funds
2,993.56a
4,450.6a
Trading financial assets
524.72a
300.71a
Accounts receivable
780.14a
688a
Receivables financing
1,185.5a
1,442.77a
Prepayments
62.03a
65.57a
Other receivables
23.06a
11.49a
Inventories
1,711.92a
1,747.69a
Other current assets
29.69a
25.85a
Total current assets
7,310.62a
8,732.68a
Non-current assets
Long-term equity investments
1,309.34a
1,415.41a
Other non-current financial assets
511.87a
638.22a
Fixed assets
3,232.21a
3,388.72a
Construction in progress
221.76a
153.87a
Right-of-use assets
194.28a
226.6a
Intangible assets
604.17a
573.64a
Development expenditures
1,445.66a
1,452.9a
Goodwill
0
15.88a
Long-term prepaid expenses
20.67a
23.22a
Deferred tax assets
53.17a
50a
Other non-current assets
72.54a
43.14a
Total non-current assets
7,665.68a
7,981.6a
Total assets
14,976.3a
16,714.29a
Current liabilities
Short-term borrowings
699.54a
723.05a
Notes payable
188.04a
128.91a
Accounts payable
418.77a
443.82a
Advances from customers
66.08a
66.36a
Contract liabilities
67.53a
89.02a
Employee benefits payable
113.61a
114.3a
Taxes payable
120.81a
85.61a
Other payables
38.26a
183.91a
Non-current liabilities due within one year
634.67a
521.28a
Other current liabilities
2.38a
13.3a
Total current liabilities
2,349.69a
2,369.56a
Non-current liabilities
Long-term borrowings
253.76a
1,414.06a
Lease liabilities
67.97a
81.52a
Deferred income
193.29a
159.02a
Deferred tax liabilities
0.4a
0.11a
Total non-current liabilities
515.41a
1,654.72a
Total liabilities
2,865.1a
4,024.28a
Owners' equity (or shareholders' equity)
Share capital
1,493.95a
1,499.7a
Capital reserves
458.96a
958.08a
Less: Treasury shares
0
105.98a
Other comprehensive income
52.22a
88a
Surplus reserve
1,743.64a
1,636.87a
Retained earnings
8,154.56a
8,291.75a
Total equity attributable to owners of the parent
11,903.33a
12,368.42a
Non-controlling interests
207.86a
321.59a
Total shareholders' equity
12,111.19a
12,690.01a
Total liabilities and shareholders' equity
14,976.3a
16,714.29a

Verified Sources Behind Tasly Pharmaceutical Group’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Tasly Pharmaceutical Group’s data sources below and access millions more through our Disclosure Search.

a. Tasly Pharmaceutical Group's Annual Report 2024
Trace every data point back to Tasly Pharmaceutical Group’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?